Genomic medicine: Genomics as a probe for disease biology

New England Journal of Medicine

Volumn 349, Issue 10, 2003, Pages 969-974

  Burke, Wylie ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; DYSTROPHIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ASTHMA; CYSTIC FIBROSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA SEQUENCE; GENE DELETION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HEMOPHILIA A; HUMAN; MEDICAL RESEARCH; MUSCULAR DYSTROPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC DISORDER; GENETICS; MUTATION;

ASTHMA; CYSTIC FIBROSIS; GENETIC DISEASES, INBORN; GENOMICS; GENOTYPE; HEMOPHILIA A; HUMANS; MUSCULAR DYSTROPHIES; MUTATION; VARIATION (GENETICS);

EID: 0041830430     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra012479     Document Type: Review

References (56)

1. Guttmacher AE, Collins FS. Genomic medicine - a primer. N Engl J Med 2002; 347:1512-20.
2. Hoyer LW. Hemophilia A. N Engl J Med 1994;330:38-47.
3. Goodeve AC, Williams I, Bray GL, Peake IR. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIIl (Recombinate). Thromb Haemost 2000;83:844-8.
4. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002;82:291-329.
5. Korf BR, Darras BT, Urion DK. Dystrophinopathies [includes: Duchenne muscular dystrophy (DMD), pseudohypertrophic muscular dystrophy, Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy (XLDCM)]. Seattle: University of Washington, 2003. (Accessed August 8, 2003, at http://www.geneclinics.org/profiles/dbmd/ details.html.)
6. Beggs AH. Dystrophinopathy, the expanding phenotype: dystrophin abnormalities in X-linked dilated cardiomyopathy. Circulation 1997;95:2344-7.
7. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333:918-24.
8. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189-95.
9. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-51.
10. Mickle JE, Cutting GR. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Clin Chest Med 1998;19:443-58.
11. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000;67:117-33.
12. Gan K-H, Veeze HJ, van den Ouweland AMW, et al. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 1995;333:95-9.
13. De Braekeleer M, Allard C, Leblanc JP, Simard F, Aubin G. Genotype-phenotype correlation in cystic fibrosis patients compound heterozygous for the A455E mutation. Hum Genet 1997;101:208-11.
14. The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993;329:1308-13.
15. Santis G, Osbome L, Knight RA, Hodson ME. Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis. Lancet 1990;336:1081-4.
16. Burke W, Aitken ML, Chen SH, Scott CR. Variable severity of pulmonary disease in adults with identical cystic fibrosis mutations. Chest 1992;102:506-9.
17. Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999;104:431-7.
18. Rozmahel R, Wilschanski M, Matin A, et al. Modulation ofdisease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996;12:280-7. [Erratum, Nat Genet 1996;13:129.]
19. Salvatore F, Scudiero O, Castaldo G. Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes. Am J Med Genet 2002;111:88-95.
20. Mekus F, Laabs U, Veeze H, Tummler B. Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs. Hum Genet 2003;112:1-11.
21. Zielenski J, Corey M, Rozmahel R, et al. Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet 1999;22:128-9.
22. Campbell PW III, Parker RA, Roberts BT, Krishnamani MR Phillips JA III. Association ofpoor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion. J Pediatr 1992;120:261-4.
23. Dipple KM, McCabe ER. Modifier genes convert "simple" Mendelian disorders to complex traits. Mol Genet Metab 2000;71: 43-50.
24. Curtis JR, Burke W, Kassner AW, Aitken ML. Absence of health insurance is associated with decreased life expectancy in patients with cystic fibrosis. Am J Respir Crit Care Med 1997;155:1921-4.
25. Britton JR. Effects of social class, sex, and region of residence on age at death from cystic fibrosis. BMJ 1989;298:483-7.
26. Dork T, Dworniczak B, Aulehla-Scholz C, et al. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet 1997;100:365-77.
27. Noone PG, Knowles MR. 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res 2001;2:328-32.
28. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921. [Errata, Nature 2001;411:720, 412:565.]
29. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348: 538-49.
30. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-37.
31. Collins FS. Shattuck Lecture - medical and societal consequences of the Human Genome Project. N Engl J Med 1999;341:28-37.
32. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. Am J Epidemiol 2000;151:839-45.
33. Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 2002;34:204-9.
34. Patino CM, Martinez FD. Interactions between genes and environment in the development of asthma. Allergy 2001;56:279-86.
35. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma - United States, 1980-1999. MMWR CDC Surveill Summ 2002;51: 1-13.
36. Palmer LJ, Silverman ES, Weiss ST, Drazen JM. Pharmacogenetics of asthma. Am J Respir Crit Care Med 2002;165:861-6.
37. Cookson WO. Asthma genetics. Chest 2002;121:Suppl:7S-13S.
38. Hakonarson H, Wjst M. Current concepts of the genetics of asthma. Curr Opin Pediatr 2001;13:267-77.
39. Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002;418:426-30.
40. Shapiro SD, Owen CA. ADAM-33 surfaces as an asthma gene. N Engl J Med 2002; 347:936-8.
41. Liggett SB. Polymorphisms of the beta2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997;156:S156-S162
42. Renauld JC. New insights into the role of cytokines in asthma. J Clin Pathol 2001; 54:577-89.
43. Spiteri MA, Bianco A, Strange RC, Fryer AA. Polymorphisms at the glutathione S-transferase, GSTP1 locus: a novel mechanism for susceptibility and development of atopic airway inflammation. Allergy 2000; 55:Suppl 6l:15-20.
44. Wang Z, Chen C, Niu T, et al. Association of asthma with beta(2)-adrenergic receptor gene polymorphism and cigarette smoking. Am J Respir Crit Care Med 2001; 163:1404-9. [Erratum, Am J Respir Crit Care Med 2002;166:775.]
45. Postma DS, Meijer GG, Koppelman GH. Definition of asthma: possible approaches in genetic studies. Clin Exp Allergy 1998;28:Suppl 1:62-6.
46. Koppelman GH Meijer GG, Postma DS. Defining asthma in genetic studies. Clin Exp Allergy 1999;29:Suppl 4:1-4.
47. Ayres J. Severe asthma phenotypes: the case for more specificity J R Soc Med 2001; 94:115-8.
48. Palmer LJ, Cookson WO. Using single nucleotide polymorphisms as a means to understanding the pathophysiology of asthma. Respir Res 2001;2:102-12.
49. Weiss ST. Association studies in asthma genetics. Am J Respir Crit Care Med 2001; 165:2014-5.
50. Little J, Bradley L, Bray MS, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002;156: 300-10.
51. Khoury MJ, Yang Q. The future of genetic studies of complex human diseases: an epidemiologic perspective. Epidemiology 1998;9:350-4.
52. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001;29:306-9.
53. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002;4:45-61.
54. Childs B, Valle D. Genetics, biology and disease. Annu Rev Genomics Hum Genet 2000;1:1-19.
55. Abbott A. A post-genomic challenge: learning to read patterns of protein synthesis. Nature 1999;402:715-20.
56. Burley SK, Almo SC, Bonanno JB, et al. Structural genomics: beyond the Human Genome Project. Nat Genet 1999;:151-7.